How to Reconstitute GHK-Cu: Storage, Stability, and Safe Dosing After Mixing

What Is GHK-Cu and Why Does Reconstitution Technique Matter?

GHK-Cu (glycyl-L-histidyl-L-lysine copper(II)) is a naturally occurring copper-binding tripeptide found in human plasma, saliva, and urine. Plasma concentrations run roughly 200 ng/mL in young adults and decline with age, a pattern documented in published tissue-repair research. The compound is sold for research and compounding purposes as a white-to-off-white lyophilized powder; it is not FDA-approved as a drug, which matters legally and practically.

Reconstitution technique matters for two reasons. First, GHK-Cu is chemically active at the copper center, making it more sensitive to oxidation, pH swings, and light exposure than many peptides. Second, an improperly mixed or stored vial can degrade silently, meaning you have no visible sign that the peptide has lost potency. Getting the diluent, volume, and storage right is not optional detail work.

What GHK-Cu Is Used for in Women's Health

Women seek GHK-Cu primarily for three applications: hair thinning (especially the diffuse pattern common in postpartum and perimenopausal women), skin quality, and wound healing after procedures. The peptide promotes collagen and glycosaminoglycan synthesis in fibroblast culture studies and has shown activity on hair follicle size in preclinical models. Human clinical trial data are thin. A small randomized trial published in 2020 found topical GHK-Cu improved scalp hair density scores, but the sample size was under 40 participants and the preparation was topical, not injected.

Women are historically under-represented in peptide trials. The data on GHK-Cu dosing and pharmacokinetics are derived almost entirely from in vitro work and small compounding-medicine case series, not sex-stratified RCTs. Every dose and stability figure in this article is extrapolated from that limited evidence base, and you should weigh it accordingly.

Choosing the Right Diluent: Bacteriostatic Water vs. Sterile Water

Bacteriostatic water is the correct diluent for GHK-Cu when the reconstituted solution will be used over multiple days. Sterile water for injection (SWFI) contains no preservative; once punctured, USP Chapter 797 standards classify it as single-use and require discard within 6 hours at room temperature or 24 hours refrigerated.

Why Bacteriostatic Water Wins

Bacteriostatic water for injection (BWFI) contains 0.9% benzyl alcohol as the preservative, which inhibits bacterial growth in the vial between uses. For a peptide you will draw from over 3-4 weeks, this is the difference between a microbiologically safe product and one that is a contamination risk after the first puncture. Bacteriostatic water is available without prescription at most pharmacies and from licensed compounding suppliers.

What to Avoid

• Normal saline (0.9% NaCl): acceptable for single-dose injection but accelerates copper peptide degradation over time due to chloride ion interaction.
• Tap water or distilled water: absolutely not. Neither is sterile.
• Acetic acid diluent (used for some peptides like BPC-157): not needed for GHK-Cu and alters solution pH unnecessarily.

Volume and pH

Bacteriostatic water has a pH of 4.5-7.0, which is compatible with GHK-Cu's stability range. The copper chelate is most stable at slightly acidic to neutral pH. Avoid alkaline diluents.

Step-by-Step Reconstitution Protocol

Work on a clean, hard surface. Wash hands for 20 seconds. Gather everything before you start.

What you need:

• GHK-Cu lyophilized vial
• Bacteriostatic water for injection (multi-dose vial)
• 1 mL or 3 mL luer-lock syringe
• 25-27 gauge 1-inch needle for drawing diluent (or a vented needle/filter needle if available)
• 29-31 gauge insulin syringe for injection
• Alcohol swabs (70% isopropyl)
• Sharps container

Step 1. Swab the rubber septum of both the BWFI vial and the GHK-Cu vial with a fresh alcohol swab. Let dry for 10 seconds.

Step 2. Draw your target volume of bacteriostatic water into the syringe. For a 50 mg vial, 1 mL gives a 50 mg/mL concentration; 2 mL gives 25 mg/mL. Choose based on your target dose (see dosing section below).

Step 3. Insert the needle into the GHK-Cu vial at a 45-degree angle. Aim the stream of water at the glass wall, not directly onto the powder cake. Direct force can shear the peptide structure.

Step 4. Do not shake. Gently swirl or roll the vial between your palms for 30-60 seconds. GHK-Cu dissolves readily and should produce a clear pale blue to blue-green solution.

Step 5. Visually inspect. The solution must be clear without visible particles. A deep blue color is normal and expected because copper(II) absorbs in that range. Cloudy, brown, or precipitated solutions mean discard.

Step 6. Label the vial with the date of reconstitution and the concentration (mg/mL). This step is mandatory for dosing safety.

Dosing Calculator: Drawing the Right Volume for Your Dose

This is where errors cluster. The formula is straightforward, but the numbers must match your reconstitution volume.

Formula:

Volume to draw (mL) = Desired dose (mg) / Concentration (mg/mL)

Worked examples:

| Reconstitution volume | Vial size | Concentration | 1 mg dose | 2 mg dose | |---|---|---|---|---| | 1 mL BWFI | 50 mg | 50 mg/mL | 0.02 mL (2 units on a 100-unit syringe) | 0.04 mL (4 units) | | 2 mL BWFI | 50 mg | 25 mg/mL | 0.04 mL (4 units) | 0.08 mL (8 units) | | 2 mL BWFI | 5 mg | 2.5 mg/mL | 0.4 mL (40 units) | 0.8 mL (80 units) |

The most common GHK-Cu research doses cited in compounding literature run from 1 mg to 3 mg per subcutaneous injection, typically 2-5 days per week. These figures are not FDA-validated dosing. They are extrapolated from compounding-medicine practice and in vitro dose-response data. No large randomized trial has established an optimal dose in women.

Using an Insulin Syringe Correctly

A 29-31 gauge insulin syringe is standard for subcutaneous GHK-Cu injection. Insulin syringes are marked in units (U-100, meaning 100 units = 1 mL). To convert mL to units, multiply by 100. So 0.04 mL = 4 units on the syringe scale.

Draw 1-2 units of air first, inject into the vial, then draw your peptide volume to reduce vacuum pressure in the vial. Subcutaneous injection sites: lower abdomen (2 inches from navel), outer thigh, or lateral upper arm. Rotate sites to prevent lipodystrophy.

Storage and Stability After Mixing

Post-reconstitution stability is the section most guides skip or understate. GHK-Cu is more temperature- and light-sensitive than simpler peptides because the copper center is redox-active.

Refrigerated Storage (2-8°C)

Store the reconstituted vial in the main body of your refrigerator, not the door (door temperature fluctuates). Wrap the vial in foil or keep it in its original box to block light. Under these conditions, compounding pharmacists and peptide-stability researchers estimate a 28-day usable window based on analogy with other copper peptide formulations and general USP 797 multi-dose vial guidelines. Beyond 28 days, discard regardless of appearance.

Room Temperature

Do not store reconstituted GHK-Cu at room temperature for more than 4-6 hours. Benzyl alcohol slows but does not stop oxidative degradation at ambient temperatures.

Freezing

The lyophilized (unreconstituted) powder can be stored frozen at -20°C for up to 24 months per most manufacturer specifications. Once reconstituted, do not freeze. Freeze-thaw cycles cause copper peptide aggregation and loss of biological activity. This is a firm rule, not a caution.

Signs of Degradation

| What you see | What it means | |---|---| | Clear pale blue-green | Normal, use as planned | | Deeper than usual blue, still clear | Likely fine; document and monitor | | Brown or grey discoloration | Oxidation; discard | | Cloudiness or floaters | Contamination or aggregation; discard | | No color (colorless solution) | Possible copper dissociation; discard |

Life-Stage Considerations: Who Is Using GHK-Cu and Why It Matters

Reproductive Years and PCOS

Women with PCOS often present with both androgenic hair thinning and inflammatory skin changes. GHK-Cu's proposed anti-inflammatory and follicle-stimulating mechanisms are theoretically relevant, but there are no PCOS-specific trials. If you have PCOS and are also using metformin or hormonal contraception, no known drug interactions with GHK-Cu exist, but this has simply not been studied. Tell your clinician before adding any peptide to an existing regimen.

Postpartum Hair Loss (Telogen Effluvium)

Postpartum telogen effluvium peaks at 3-6 months after delivery and affects up to 50% of postpartum women. GHK-Cu is sometimes suggested in online communities for this indication. The evidence does not support it as a first-line intervention. Postpartum hair loss is largely self-limiting and resolves within 12 months without treatment in most cases. If you are breastfeeding, see the pregnancy and lactation section below before considering any injectable peptide.

Perimenopause and Postmenopause

Estrogen decline reduces dermal collagen density by approximately 30% in the first 5 years after menopause, which is why perimenopausal and postmenopausal women are the demographic most interested in collagen-promoting peptides. GHK-Cu's fibroblast-stimulating activity is biologically plausible in this context. Whether the peptide compensates meaningfully for estrogen-driven collagen loss has not been tested in a randomized trial in menopausal women. Systemic hormone therapy, which has direct evidence for skin quality improvement, remains the better-studied option per The Menopause Society 2023 position statement.

Pregnancy, Lactation, and Contraception

GHK-Cu is not established as safe in pregnancy or breastfeeding. This is a hard stop.

There are no human studies of GHK-Cu in pregnant women. Animal reproductive toxicity data are sparse. The compound has not been assigned an FDA pregnancy category under the old classification system, and it does not appear in the current FDA labeling framework because it is not an approved drug. Copper homeostasis changes significantly during pregnancy: serum copper and ceruloplasmin rise by 50-100% across gestation as part of normal physiology. Introducing exogenous copper peptide during this period carries theoretical risks of disrupting this regulated balance, though no direct toxicity data exist in humans.

If you are pregnant: Do not use injectable or topical GHK-Cu. The risk-benefit calculus does not favor a cosmetic or hair peptide with zero human pregnancy safety data.

If you are breastfeeding: Copper transfers into breast milk. Whether exogenous GHK-Cu increases infant copper exposure via milk has not been studied. Avoid use until after you have finished breastfeeding and speak to your clinician.

If you are of reproductive age and not using reliable contraception: GHK-Cu is not a known teratogen, but because safety data are absent, use effective contraception if there is any possibility of pregnancy during a treatment course.

Contraception interactions: No pharmacokinetic interaction between GHK-Cu and hormonal contraceptives has been identified or studied.

Who Is This Right For, and Who Should Avoid It?

Potentially appropriate candidates

• Women with diffuse hair thinning in the perimenopausal or postmenopausal period who have already ruled out thyroid dysfunction, iron deficiency, and hormonal causes.
• Women seeking adjunct skin-quality support who understand the evidence is preclinical or small-trial at best.
• Women working with a licensed compounding pharmacy that has sourced GHK-Cu from a facility registered with the FDA under 503B outsourcing rules.

Women who should avoid or defer

• Pregnant or breastfeeding (see above).
• Women with Wilson's disease or other copper-metabolism disorders. GHK-Cu is contraindicated; excess copper accumulation is dangerous.
• Women with active infections at planned injection sites.
• Anyone sourcing peptide from unregulated online "research chemical" vendors where purity and sterility are not independently verified. FDA has issued warnings about compounded peptides from unregistered facilities.
• Women with a history of keloid formation or abnormal wound healing (GHK-Cu stimulates fibroblast activity, which may not be desirable in this context).

Topical vs. Injectable GHK-Cu: A Brief Note on Reconstitution Differences

Most published skin and hair data on GHK-Cu use topical formulations, not subcutaneous injection. Topical GHK-Cu in a serum or cream carrier requires no reconstitution by the user if purchased from a licensed compounding pharmacy. If you are mixing a topical from lyophilized powder, the same sterility principles apply, but concentration and carrier choice differ substantially from injectable prep.

For topical use, reconstitution into sterile saline or distilled water at 0.1-1% concentration is common in compounding references, but this does not fall under the same multi-dose injection-safety rules. Topical preparations should still be refrigerated and discarded after 28-30 days. Topical route is likely the safer starting point for women who have not previously used peptide injections.

Common Reconstitution Mistakes and How to Avoid Them

Mistake 1: Shaking the vial vigorously. Peptide bonds can be disrupted by mechanical shearing. Swirl gently.

Mistake 2: Using sterile water and storing for weeks. Without benzyl alcohol, a multi-use vial is not microbiologically safe beyond 24 hours refrigerated. Use bacteriostatic water.

Mistake 3: Storing in the refrigerator door. Temperature cycling every time the door opens speeds degradation. Main body of the fridge only.

Mistake 4: Skipping the label. Without the reconstitution date and concentration written on the vial, you cannot safely calculate doses or know when to discard.

Mistake 5: Drawing from a vial that has changed color to brown. Brown color indicates oxidation of the copper center. The peptide activity is compromised. Discard.

Mistake 6: Reconstituting into a very small volume to get a high concentration. Concentrations above 50 mg/mL may exceed the peptide's solubility in aqueous diluent and lead to precipitation. Stay at or below 50 mg/mL.

Regulatory and Quality-Sourcing Note

GHK-Cu is not an FDA-approved pharmaceutical. It is sold legally in the United States as a research chemical or through compounding pharmacies under specific conditions. FDA's 503A and 503B compounding frameworks govern what compounding pharmacies may prepare and for whom.

For injectable peptides, sourcing from a state-licensed 503A compounding pharmacy (requires a valid prescription) or an FDA-registered 503B outsourcing facility gives you the highest assurance of purity, sterility testing, and labeled potency. Research-chemical vendors are not required to meet pharmaceutical manufacturing standards. Certificate of Analysis (CoA) documents should show HPLC purity above 98% and mass spectrometry confirmation of molecular weight. Ask for the CoA before purchasing.